{"title":"维持性血液透析患者血清hepcidin水平与心血管疾病的关系","authors":"Y Xu, Y Wang, H Hu, J Li, T Tian","doi":"10.1556/2060.2020.00040","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To investigate the serum level of hepcidin and its relationship with cardiovascular disease (CVD) in maintenance hemodialysis (MHD) patients.</p><p><strong>Methods: </strong>Blood was obtained from 75 MHD patients before undergoing hemodialysis and 20 healthy controls. Serum hepcidin, advanced oxidation protein products (AOPP) and interleukin (IL)-6 were measured by enzyme-linked immunosorbant assay (ELISA). Spearman correlation, and binary logistic regression linear regression analyses were used to assess the relationship between serum hepcidin and other parameters.</p><p><strong>Results: </strong>The serum level of hepcidin, AOPP and IL-6 was significantly up-regulated in MHD patients compared with the control (P < 0.05). Furthermore, serum hepcidin levels in patients with CVD were higher than those in patients without CVD (P < 0.05). In all MHD patients, serum hepcidin level was correlated positively with erythropoietin (EPO) dose per week (ρ = 0.251, P = 0.030), EPO resistance index (ρ = 0.268, P = 0.020), ferritin (ρ = 0.814, P < 0.001), transferin saturation (TSAT, ρ = 0.263, P = 0.023), AOPP (ρ = 0.280, P = 0.049), high sensitive C reactive protein (ρ = 0.151, P = 0.006), IL-6 (ρ = 0.340, P = 0.003) and left ventricular mass index (LVMI, ρ = 0.290, P = 0.033). Moreover, it was negatively correlated with serum pre-albumin (ρ = -0.266, P = 0.021), total iron-binding capacity (TIBC, ρ = -0.458, P < 0.001), unsaturated iron-binding capacity (UIBC, ρ = -0.473, P < 0.001) and transferrin (ρ = -0.487, P < 0.001). Linear regression analysis showed that ferritin (β = 0.708, P < 0.001), TIBC (β = -0.246, P = 0.032) and IL-6 (β = 0.209, P = 0.041) were independently associated with hepcidin. Results of binary logistic regression analysis suggested that higher serum hepcidin level (>249.2 ng/mL) was positively and independently related to CVD (OR = 1.32, 95% CI [1.20-9.56], P = 0.043).</p><p><strong>Conclusions: </strong>Serum hepcidin level is associated with CVD in MHD patients, indicating that hepcidin may be a novel biomarker and therapeutic target for CVD.</p>","PeriodicalId":20058,"journal":{"name":"Physiology international","volume":"107 4","pages":"491-500"},"PeriodicalIF":2.2000,"publicationDate":"2020-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Relationship between serum hepcidin levels and cardiovascular disease in patients with maintenance hemodialysis.\",\"authors\":\"Y Xu, Y Wang, H Hu, J Li, T Tian\",\"doi\":\"10.1556/2060.2020.00040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To investigate the serum level of hepcidin and its relationship with cardiovascular disease (CVD) in maintenance hemodialysis (MHD) patients.</p><p><strong>Methods: </strong>Blood was obtained from 75 MHD patients before undergoing hemodialysis and 20 healthy controls. Serum hepcidin, advanced oxidation protein products (AOPP) and interleukin (IL)-6 were measured by enzyme-linked immunosorbant assay (ELISA). Spearman correlation, and binary logistic regression linear regression analyses were used to assess the relationship between serum hepcidin and other parameters.</p><p><strong>Results: </strong>The serum level of hepcidin, AOPP and IL-6 was significantly up-regulated in MHD patients compared with the control (P < 0.05). Furthermore, serum hepcidin levels in patients with CVD were higher than those in patients without CVD (P < 0.05). In all MHD patients, serum hepcidin level was correlated positively with erythropoietin (EPO) dose per week (ρ = 0.251, P = 0.030), EPO resistance index (ρ = 0.268, P = 0.020), ferritin (ρ = 0.814, P < 0.001), transferin saturation (TSAT, ρ = 0.263, P = 0.023), AOPP (ρ = 0.280, P = 0.049), high sensitive C reactive protein (ρ = 0.151, P = 0.006), IL-6 (ρ = 0.340, P = 0.003) and left ventricular mass index (LVMI, ρ = 0.290, P = 0.033). Moreover, it was negatively correlated with serum pre-albumin (ρ = -0.266, P = 0.021), total iron-binding capacity (TIBC, ρ = -0.458, P < 0.001), unsaturated iron-binding capacity (UIBC, ρ = -0.473, P < 0.001) and transferrin (ρ = -0.487, P < 0.001). Linear regression analysis showed that ferritin (β = 0.708, P < 0.001), TIBC (β = -0.246, P = 0.032) and IL-6 (β = 0.209, P = 0.041) were independently associated with hepcidin. Results of binary logistic regression analysis suggested that higher serum hepcidin level (>249.2 ng/mL) was positively and independently related to CVD (OR = 1.32, 95% CI [1.20-9.56], P = 0.043).</p><p><strong>Conclusions: </strong>Serum hepcidin level is associated with CVD in MHD patients, indicating that hepcidin may be a novel biomarker and therapeutic target for CVD.</p>\",\"PeriodicalId\":20058,\"journal\":{\"name\":\"Physiology international\",\"volume\":\"107 4\",\"pages\":\"491-500\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2020-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Physiology international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1556/2060.2020.00040\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHYSIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physiology international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1556/2060.2020.00040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
引用次数: 4
摘要
背景:探讨维持性血液透析(MHD)患者血清hepcidin水平及其与心血管疾病(CVD)的关系。方法:75例MHD患者行血液透析前采血，20例健康对照。采用酶联免疫吸附试验(ELISA)检测血清hepcidin、晚期氧化蛋白产物(AOPP)和白细胞介素(IL)-6。采用Spearman相关和二元logistic回归线性回归分析评价血清hepcidin与其他参数的关系。结果:MHD患者血清hepcidin、AOPP、IL-6水平较对照组明显升高(P < 0.05)。CVD患者血清hepcidin水平高于无CVD患者(P < 0.05)。磁流体动力患者,血清hepcidin水平将积极与促红细胞生成素(EPO)每周剂量(ρ= 0.251,P = 0.030),促红细胞生成素抵抗指数(ρ= 0.268,P = 0.020),铁蛋白(ρ= 0.814,P < 0.001), transferin饱和(TSATρ= 0.263,P = 0.023), AOPP(ρ= 0.280,P = 0.049),高灵敏度C反应蛋白(ρ= 0.151,P = 0.006), il - 6(ρ= 0.340,P = 0.003)和左心室质量指数(LVMIρ= 0.290,P = 0.033)。与血清前白蛋白(ρ = -0.266, P = 0.021)、总铁结合能力(TIBC， ρ = -0.458, P < 0.001)、不饱和铁结合能力(UIBC， ρ = -0.473, P < 0.001)、转铁蛋白(ρ = -0.487, P < 0.001)呈负相关。线性回归分析显示，铁蛋白(β = 0.708, P < 0.001)、TIBC (β = -0.246, P = 0.032)和IL-6 (β = 0.209, P = 0.041)与hepcidin独立相关。二元logistic回归分析结果显示血清hepcidin水平升高(>249.2 ng/mL)与CVD呈正相关且独立相关(OR = 1.32, 95% CI [1.20 ~ 9.56]， P = 0.043)。结论:MHD患者血清hepcidin水平与CVD相关，提示hepcidin可能是一种新的CVD生物标志物和治疗靶点。
Relationship between serum hepcidin levels and cardiovascular disease in patients with maintenance hemodialysis.
Background: To investigate the serum level of hepcidin and its relationship with cardiovascular disease (CVD) in maintenance hemodialysis (MHD) patients.
Methods: Blood was obtained from 75 MHD patients before undergoing hemodialysis and 20 healthy controls. Serum hepcidin, advanced oxidation protein products (AOPP) and interleukin (IL)-6 were measured by enzyme-linked immunosorbant assay (ELISA). Spearman correlation, and binary logistic regression linear regression analyses were used to assess the relationship between serum hepcidin and other parameters.
Results: The serum level of hepcidin, AOPP and IL-6 was significantly up-regulated in MHD patients compared with the control (P < 0.05). Furthermore, serum hepcidin levels in patients with CVD were higher than those in patients without CVD (P < 0.05). In all MHD patients, serum hepcidin level was correlated positively with erythropoietin (EPO) dose per week (ρ = 0.251, P = 0.030), EPO resistance index (ρ = 0.268, P = 0.020), ferritin (ρ = 0.814, P < 0.001), transferin saturation (TSAT, ρ = 0.263, P = 0.023), AOPP (ρ = 0.280, P = 0.049), high sensitive C reactive protein (ρ = 0.151, P = 0.006), IL-6 (ρ = 0.340, P = 0.003) and left ventricular mass index (LVMI, ρ = 0.290, P = 0.033). Moreover, it was negatively correlated with serum pre-albumin (ρ = -0.266, P = 0.021), total iron-binding capacity (TIBC, ρ = -0.458, P < 0.001), unsaturated iron-binding capacity (UIBC, ρ = -0.473, P < 0.001) and transferrin (ρ = -0.487, P < 0.001). Linear regression analysis showed that ferritin (β = 0.708, P < 0.001), TIBC (β = -0.246, P = 0.032) and IL-6 (β = 0.209, P = 0.041) were independently associated with hepcidin. Results of binary logistic regression analysis suggested that higher serum hepcidin level (>249.2 ng/mL) was positively and independently related to CVD (OR = 1.32, 95% CI [1.20-9.56], P = 0.043).
Conclusions: Serum hepcidin level is associated with CVD in MHD patients, indicating that hepcidin may be a novel biomarker and therapeutic target for CVD.
期刊介绍：
The journal provides a forum for important new research papers written by eminent scientists on experimental medical sciences. Papers reporting on both original work and review articles in the fields of basic and clinical physiology, pathophysiology (from the subcellular organization level up to the oranizmic one), as well as related disciplines, including history of physiological sciences, are accepted.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
